As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2024 about Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies can be found below.